Kidney cancer vaccine trial pulled before it began

NCT ID NCT06708936

Terminated ⭐️ VACCINE ⭐️ Sponsor: Kousai Bio Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase study aimed to test a new vaccine called KSD-201 in people with advanced clear cell renal cell carcinoma whose cancer had stopped responding to standard treatments. The vaccine uses the patient's own immune cells to try to fight the cancer. However, the trial was withdrawn before any participants were enrolled, so no data on safety or effectiveness were collected.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KSD-201 (dendritic cell vaccine)
What this could lead to: If it works, this could point toward a new vaccine-based treatment for advanced kidney cancer that has stopped responding to standard therapy.
What could go wrong: This trial was withdrawn before enrolling any participants, so no results are available. It was an early-phase study with a small planned sample, so even if conducted, success would be uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clear cell renal carcinoma nonpapillary renal cell carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLEAR CELL RENAL CELL CARCINOMA (CCRCC)

Contacts and locations

Locations

Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology

Wuhan, Hubei, 430000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.